Sahajanand Medical Technologies Limited (SMT)
Snapshot
Exchange activity23 Oct 2026
- Delivery
- 43.67%
- Bulk & block deals
- 4 in 60 days
Exchange data. Each figure as its own page shows it; the dates are the data's. Information only, not investment advice.
📈 Share price & events
SMT delivery percentage and bulk deals
NSE end-of-day data for
On Fri, 23 Oct 2026, 43.67% of the SMT shares traded on NSE were taken to delivery. The stock has too few sessions on record for a normal to compare with. 4 bulk or block deals were reported in SMT in the last 60 days: ₹155 Cr bought and ₹21 Cr sold.
| Date | Side | Counterparty | Value | Price | Quantity | Type |
|---|---|---|---|---|---|---|
| 23 Oct | Buy | Invesco Mutual Fund | ₹104.28 Cr | ₹371.44 | 2,807,366 | Bulk |
| 23 Oct | Buy | Invesco Mutual Fund | ₹29.99 Cr | ₹374.91 | 800,000 | Bulk |
| 23 Oct | Sell | Grt Strategic Ventures Llp | ₹20.58 Cr | ₹382.54 | 538,038 | Bulk |
| 23 Oct | Buy | Grt Strategic Ventures Llp | ₹20.57 Cr | ₹382.37 | 538,038 | Bulk |
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Sahajanand Medical Technologies (SMT) has received a summons dated October 16, 2026 (received October 23, 2026) issued under Section 70 of the CGST Act, 2017 by the DGGI Mumbai Zonal Unit. The inquiry calls for verification of books of accounts and evidence concerning GST compliance on reimbursements made to foreign subsidiaries for clinical trials. The company stated that no specific violations are alleged and there is no material financial, operational, or business impact at this stage.
- Summons received under Section 70 of the CGST Act, 2017 from DGGI Mumbai Zonal Unit
- Dated October 16, 2026, and received by the company on October 23, 2026
- Inquiry pertains to GST compliance on reimbursements made to foreign subsidiaries for clinical trials
- No material financial, operational, or business impact identified at this stage
Sahajanand Medical Technologies Limited submitted a regulatory intimation under Regulation 6(1) of SEBI LODR Regulations, 2015. The filing confirms the appointment of Ms. Deepshikha Singhal (ACS - 35992) as Company Secretary & Compliance Officer effective April 01, 2025. The appointment was approved by the Board of Directors at its meeting held on April 16, 2025. This submission is purely procedural and confirms her role as Key Managerial Personnel in whole-time employment.
- Appointment of Ms. Deepshikha Singhal (ACS – 35992) as Company Secretary & Compliance Officer
- Effective date of appointment is April 01, 2025
- Board approval granted at meeting on April 16, 2025
- Filing made under SEBI Listing Regulations 6(1) on October 23, 2026
Sahajanand Medical Technologies Limited has submitted a routine regulatory disclosure under Regulation 30(5) of the SEBI LODR Regulations, 2015. The filing authorizes three Key Managerial Personnel (KMPs) to determine materiality of events and disclose them to stock exchanges. The designated personnel include MD & CEO Bhargav Dhirajlal Kotadia, CFO Amit Kumar Khandelia, and Company Secretary Deepshikha Singhal. The update has no financial or operational impact on the company.
- Disclosure submitted pursuant to Regulation 30(5) of SEBI LODR Regulations, 2015 on October 23, 2026
- Total of 3 Key Managerial Personnel authorized to assess and report material events
- Designated KMPs include MD & CEO Bhargav Dhirajlal Kotadia, CFO Amit Kumar Khandelia, and CS Deepshikha Singhal
- Single contact number provided for general disclosures: 022 49564000
Company profile
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
